Autoimmune Hemolytic Anemia Overview

Save information for later
Sign Up

Learn About Autoimmune Hemolytic Anemia

View Main Condition: Anemia

What is the definition of Autoimmune Hemolytic Anemia?
Autoimmune hemolytic anemia (AIHA) occurs when your immune system makes antibodies that attack your red blood cells. This causes a drop in the number of red blood cells, leading to hemolytic anemia. Symptoms may include unusual weakness and fatigue with tachycardia and breathing difficulties, jaundice, dark urine and/or splenomegaly. AIHA can be primary (idiopathic) or result from an underlying disease or medication. The condition may develop gradually or occur suddenly.
What are the alternative names for Autoimmune Hemolytic Anemia?
  • Autoimmune hemolytic anemia
  • Acquired autoimmune hemolytic anemia
  • Anemia hemolytic autoimmune
  • Familial auto-immune hemolytic anemia (subtype)
  • Idiopathic autoimmune hemolytic anemia
  • Immuno-hemolytic anemia
Who are the top Autoimmune Hemolytic Anemia Local Doctors?
Dr. Donald P. Quick
Hematology Oncology | Hematology | Oncology
Dr. Donald P. Quick
Hematology Oncology | Hematology | Oncology

Covenant Medical Group

2215 Nashville Ave, 
Lubbock, TX 
 (2.5 mi)
806-725-5844
Languages Spoken:
English, Filipino, Hindi, Spanish
See accepted insurances
Accepting New Patients

Donald Quick is a Hematologist Oncology specialist and a Hematologist in Lubbock, Texas. Dr. Quick and is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Non-Hodgkin Lymphoma, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Hemangioma Thrombocytopenia Syndrome, and Bone Marrow Aspiration. Dr. Quick is currently accepting new patients.

Dr. Davor Vugrin
Hematology Oncology
Dr. Davor Vugrin
Hematology Oncology
2232 Indiana Ave, Suite 102, 
Lubbock, TX 
 (1.9 mi)
806-793-0988
Languages Spoken:
English

Davor Vugrin is a Hematologist Oncology provider in Lubbock, Texas. Dr. Vugrin and is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, Lynch Syndrome, and Autoimmune Hemolytic Anemia.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Lukman A. Tijani
Hematology Oncology | Oncology | Hematology
Dr. Lukman A. Tijani
Hematology Oncology | Oncology | Hematology

Texas Tech University Health Sciences Center Lubbock

602 Indiana Ave, 
Lubbock, TX 
 (2.1 mi)
806-743-3150
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lukman Tijani is a Hematologist Oncology specialist and an Oncologist in Lubbock, Texas. Dr. Tijani and is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Neuroendocrine Tumor, Bone Marrow Aspiration, and Endoscopy. Dr. Tijani is currently accepting new patients.

View All Doctors
What are the latest Autoimmune Hemolytic Anemia Clinical Trials?
A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment
A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment
Enrollment Status: Recruiting
Publish Date: February 17, 2025
Intervention Type: Biological, Drug
Study Phase: Phase 3

Summary: The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension
Who is this study for: Adult patients with Warm Autoimmune Hemolytic Anemia
Enrollment Status: Recruiting
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drug: M281
Study Phase: Phase 2/Phase 3

Summary: The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center